CO2019006220A2 - Compuestos de pirazolopirimidina y métodos de uso de los mismos - Google Patents

Compuestos de pirazolopirimidina y métodos de uso de los mismos

Info

Publication number
CO2019006220A2
CO2019006220A2 CONC2019/0006220A CO2019006220A CO2019006220A2 CO 2019006220 A2 CO2019006220 A2 CO 2019006220A2 CO 2019006220 A CO2019006220 A CO 2019006220A CO 2019006220 A2 CO2019006220 A2 CO 2019006220A2
Authority
CO
Colombia
Prior art keywords
methods
pyrazolopyrimidine compounds
compounds
pyrazolopyrimidine
formula
Prior art date
Application number
CONC2019/0006220A
Other languages
English (en)
Inventor
Guiling Zhao
Limin Cheng
Mark Zak
F Anthony Romero
Paul Gibbons
Wei Li
Yun-Xing Cheng
Po-Wai Yuen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2019006220A2 publication Critical patent/CO2019006220A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En el presente documento se describen compuestos de fórmula (IA) o una sal farmacéuticamente aceptable de los mismos y métodos de uso como inhibidores de Janus cinasa.
CONC2019/0006220A 2016-12-29 2019-06-14 Compuestos de pirazolopirimidina y métodos de uso de los mismos CO2019006220A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016112932 2016-12-29
PCT/EP2017/084569 WO2018122212A1 (en) 2016-12-29 2017-12-22 Pyrazolopyrimidine compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2019006220A2 true CO2019006220A2 (es) 2019-06-28

Family

ID=61094385

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0006220A CO2019006220A2 (es) 2016-12-29 2019-06-14 Compuestos de pirazolopirimidina y métodos de uso de los mismos

Country Status (18)

Country Link
US (1) US11155557B2 (es)
EP (1) EP3562809B1 (es)
JP (1) JP6900491B2 (es)
KR (1) KR20190100337A (es)
CN (1) CN110114343B (es)
AU (1) AU2017385543A1 (es)
BR (1) BR112019013287A2 (es)
CA (1) CA3046435A1 (es)
CL (1) CL2019001694A1 (es)
CO (1) CO2019006220A2 (es)
CR (1) CR20190310A (es)
IL (1) IL267671A (es)
MA (1) MA47167A (es)
MX (1) MX2019007339A (es)
PE (1) PE20191236A1 (es)
PH (1) PH12019501022A1 (es)
RU (1) RU2019123319A (es)
WO (1) WO2018122212A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019013287A2 (pt) 2016-12-29 2019-12-24 Hoffmann La Roche compostos de pirazolopirimidina e métodos de uso dos mesmos
TW201902896A (zh) 2017-05-22 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療化合物及組合物及其使用方法
CN111587250A (zh) * 2018-01-15 2020-08-25 豪夫迈·罗氏有限公司 作为jak抑制剂的吡唑并嘧啶化合物
WO2020257145A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
EP3986899A1 (en) * 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
JP2022536805A (ja) * 2019-06-18 2022-08-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｊａｋキナーゼのテトラゾール置換ピラゾロピリミジン阻害剤及びその使用
WO2022175829A1 (en) * 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
TW202421149A (zh) * 2022-09-09 2024-06-01 義大利商吉斯藥品公司 作為Janus激酶抑制劑之雜環衍生物
WO2024052512A1 (en) * 2022-09-09 2024-03-14 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP0842195A1 (en) 1995-07-06 1998-05-20 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
ES2271365T3 (es) 2001-12-20 2007-04-16 Bayer Healthcare Ag Derivados de 1,4-dihidro-1,4-difenilpiridina.
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
CN102131389A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
CN109970743B (zh) * 2014-05-23 2022-03-04 豪夫迈·罗氏有限公司 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
EP3416967B1 (en) 2016-02-18 2022-02-09 F. Hoffmann-La Roche AG Therapeutic compounds, compositions and methods of use thereof
IL263934B2 (en) 2016-06-29 2023-10-01 Hanmi Pharm Ind Co Ltd A derivative of glucagon, its conjugate, a preparation containing it and its medical use
BR112019013287A2 (pt) 2016-12-29 2019-12-24 Hoffmann La Roche compostos de pirazolopirimidina e métodos de uso dos mesmos

Also Published As

Publication number Publication date
IL267671A (en) 2019-08-29
PE20191236A1 (es) 2019-09-11
RU2019123319A3 (es) 2021-02-01
PH12019501022A1 (en) 2019-12-16
EP3562809B1 (en) 2021-06-09
CN110114343B (zh) 2022-09-06
CA3046435A1 (en) 2018-07-05
KR20190100337A (ko) 2019-08-28
AU2017385543A1 (en) 2019-05-23
CN110114343A (zh) 2019-08-09
EP3562809A1 (en) 2019-11-06
CR20190310A (es) 2019-08-21
WO2018122212A1 (en) 2018-07-05
MA47167A (fr) 2019-11-06
RU2019123319A (ru) 2021-02-01
US11155557B2 (en) 2021-10-26
US20190345165A1 (en) 2019-11-14
JP2020503339A (ja) 2020-01-30
JP6900491B2 (ja) 2021-07-07
MX2019007339A (es) 2019-09-06
BR112019013287A2 (pt) 2019-12-24
CL2019001694A1 (es) 2019-11-22

Similar Documents

Publication Publication Date Title
CO2019006220A2 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos
CL2019002032A1 (es) Procesos para preparar un inhibidor de jak1 (divisional de solicitud 1790-2018).
DOP2018000089A (es) Amidas heterocíclicas como inhibidores de cinasas
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CO2017011754A2 (es) Amidas heterocíclicas como inhibidores de quinasa
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
DOP2017000015A (es) Compuestos de heteroarilo y sus usos
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
ECSP17054980A (es) Inhibidores selectivos de bace1
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CU20150053A7 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
DOP2019000184A (es) Inhibidores selectivos de jak1
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
EA201991595A1 (ru) Активатор nrf2
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos